<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233739</url>
  </required_header>
  <id_info>
    <org_study_id>RIZACONDRO</org_study_id>
    <nct_id>NCT01233739</nct_id>
  </id_info>
  <brief_title>Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis.</brief_title>
  <official_title>Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Measurement With Sensory and Quantitive Functional Tests and Concordance Analysis With Subjective Scales of Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan A. Arnaiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who present rhizarthrosis diagnostic will be randomized to be treated with&#xD;
      chondroitin sulfate or placebo during 24 weeks to study the effect of the treatment with&#xD;
      objective and subjective indicators of pain and sensibility.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation with visual analogue pain scale as mean at the last weak</measure>
    <time_frame>36 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sollerman test</measure>
    <time_frame>36 weeks</time_frame>
    <description>Evaluation of hand function with Sollerman test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand pressure force</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thumb-index finger pincer force</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dash test</measure>
    <time_frame>36 weeks</time_frame>
    <description>Osteoarthritis functional test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 test</measure>
    <time_frame>36 weeks</time_frame>
    <description>Quality of life test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical sensitivity measured with electronic Von Frey filament</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vibratory and thermic sensibility threshold assisted by computer</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of paracetamol or other analgesic drugs</measure>
    <time_frame>36 weeks</time_frame>
    <description>recorded in a patient diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of trapezium-thumb metacarpal joint by ultrasound scan</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic evaluation</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical evaluation</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Rhizarthrosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chondroitin sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 2 capsules of 400 mg of chondroitin sulfate orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chondroitin sulfate</intervention_name>
    <description>Administration of 2 capsules of 400 mg of chondroitin sulfate orally.</description>
    <arm_group_label>Chondroitin sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of 2 capsules of placebo orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  both sex patients&#xD;
&#xD;
          -  age between 45 to 75 years&#xD;
&#xD;
          -  with mechanical pain at the trapezium-thumb metacarpal joint of more than 3 months&#xD;
             duration&#xD;
&#xD;
          -  grade II or III Eaton &amp; Glickel rhizarthrosis radiological diagnose&#xD;
&#xD;
          -  pain at inclusion of &gt;= 40 mm at a visual analogue scale&#xD;
&#xD;
          -  without rehabilitation treatment or infiltration in the last 6 months&#xD;
&#xD;
          -  who accept to participate and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with rhizarthrosis resulted from rheumatic disease&#xD;
&#xD;
          -  patients with joint surgery or traumatic background&#xD;
&#xD;
          -  illiterate patients or unable to understand informed consent&#xD;
&#xD;
          -  patients with previous neuropsychopathology enough severe to unable participation at&#xD;
             the study&#xD;
&#xD;
          -  patients with peripheral sensory impairment due to diabetes, peripheral neuropathy or&#xD;
             central neurological sequelae of disease in the affected limb that can alter sensory&#xD;
             perception&#xD;
&#xD;
          -  patients with coagulopathy&#xD;
&#xD;
          -  inflammation for other process at the joint at study&#xD;
&#xD;
          -  in treatment with non-steroidal anti-inflammatory drug in the last 7 days and/or&#xD;
             corticosteroid in the last 30 days&#xD;
&#xD;
          -  allergy or hypersensibility at chondroitin sulfate or its excipients&#xD;
&#xD;
          -  pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquím Forés, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic i Provincial de Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judit Pich, Pharmacist</last_name>
    <phone>+34 93 227 54 00</phone>
    <phone_ext>2336</phone_ext>
    <email>jpich@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08038</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joaquim Forés, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>February 21, 2013</last_update_submitted>
  <last_update_submitted_qc>February 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Juan A. Arnaiz</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>rhizarthrosis</keyword>
  <keyword>Chondroitin sulfate</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

